David Magnin is a Professor of Chemistry at Morris College. In this capacity, he is responsible for teaching general chemistry, organic chemistry and biochemistry and was recognized by Who’s Who Among America’s Teachers. Prior to joining Morris College, he held the position of Senior Research Investigator at the Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Magnin’s work focused on the identification of superior drug candidates through the optimization of the clinical candidates in the fields of: HMG-CoA Reductase, Squalene Synthase, MTP, aP2, and DPP-4.
Among his significant accomplishments’ is the discovery of two FDA approved drugs: Lomitapide and Saxagliptin. Lomitapide (Juxtapid) is approved as a novel treatment for patients with familial chylomicronemia, a disorder for individuals who maintain life threating triglyceride/cholesterol levels. The Lomitapide project was recognized by the American Chemical Society for excellence and resulted in Dr. Magnin receiving the Heroes of Chemistry Award. Additionally, his work on DPP-IV inhibitors resulted in the discovery of Saxagliptin (Onglyza) for the treatment of diabetes. Onglyza is marketed by Astra Zeneca and has earnings of nearly a billion dollars annually. Dr. Magnin’s research has resulted nearly 100 publications and patents.
Previously, Dr. Magnin was accredited as an ordained minister through Elim Fellowship. Dr. Magnin served on the board of directors for Hope Street Ministries; Hope Street was founded to aid and feed the homeless. He is a teacher and group leader. Of particular interest to him are the topics of grace, inner healing and the history of renewal. David has been very happily married to his wife Linda for twenty-eight years; the couple has three amazing children and an even more amazing daughter in law. Dr. Magnin will be teaching on inner healing.